“Currently More Than 10 Ferroptosis Targeting Drugs Are In Clinical Trials”
In the intricate landscape of cancer therapeutics, the spotlight has shifted towards reducing the risk of cancer death, unveiling novel opportunities for precision interventions. In the recent years, the discovery of ferroptosis targeting therapies has emerged as a game changing player for the treatment of various malignancies, such as cancer diseases, autoimmune, inflammatory, eye diseases, kidney ailments, cardiovascular disorders, etc.
In dichotomy with known regulated cell death pathways, like necrosis and apoptosis, ferroptosis is an innovative form of cell death which is categorized by iron ion gathering as well as considerable lipid peroxidation mediated membrane damage. Since, the conventional therapies, like radiotherapy, chemotherapy or targeted therapy, have illustrated significant response in the treatment of cancer malignancies; however, the come along with one of the key difficulties i.e. development of drug resistance. To prevent the progression of drug resistance, ferroptosis cancer therapy can be considered as promising approach.
Download Research:
Furthermore, combination of ferroptosis with radiotherapy, chemotherapy in conjugation with immunotherapy has displayed auspicious results in preclinical studies. Additionally, the data from modern studies suggests that ferroptosis targeting therapies can also be utilized with other contemporary therapy, like nanotechnology, photodynamic therapy, magnetic field, sono dynamic therapy, for the management of various ailments, including neurodegenerative diseases, viral infections, cancer, autoimmune and list goes on. Few reasons which influence the market growth of ferroptosis targeting therapies include rise in research and development, upsurge in preclinical, translational as well as clinical trials, mounting collaborations together with investments, FDA designations, increasing cancer and other diseases incidences and fatalities.
For instance, Utreloxastat, also known as PTC857, is a 15 lipoxygenase inhibitor developed by PTC Therapeutics has received EMA Orphan Medicinal Product, in 2022, for the treatment of nuemrus patietns suffering from amyotrophic lateral sclerosis. Moreover, Vatiquinone (PTC-743) has also received FDA and EMA Orphan Drug designation as well as FDA Fast Track designation to treat Friedreich’s ataxia (FA).
Coupled with that, scientific progressions in areas like drug delivery systems, nanoparticle formulations, and targeted therapies have facilitated the development of more effective and specific ferroptosis targeting agents, contributing to market expansion. Additionally, increasing research and development investments from pharmaceutical companies, academic institutions, and research organizations have recognized the potential of ferroptosis targeting therapies and are driving innovation in addition to ferroptosis market growth.
Apart from that, many grants in order to encourage and initiate surplus studies for ferroptosis targeting therapies have been received to numerous scientists. For instance, professor at University of Würzburg, based in Germany, has received ERC Consolidator Grant worth EUR 2 Million (US$ 2.15 Million) to research the regulation of ferroptosis in November 2023.
In spite of promising results witnessed in ferroptosis targeting cell therapies, the global market for this innovative modality faces several significant challenges, such as long term safety and efficacy concerns, translation of preclinical findings into clinical applications, competition from other therapies, complex and multifaceted nature of ferroptosis which must be addressed to drive further growth and widespread adoption.
As of May 2024, the preclinical in conjugation with clinical research market of global ferroptosis targeting cell therapy for the management of cancer, autoimmune and neurodegenerative diseases have reached late phase of development; whereas ferroptosis targeting therapies for viral infections, cardiovascular diseases, eye illness and others are in early phase studies. Even though, the clinical trials market has increased, currently the US dominating ferroptosis targeting therapy realm.
At last, with the increasing prevalence of cancer along with other diseases, including autoimmune as well as inflammatory diseases, viral, bacterial, diabetes, etc. at an alarming gait urges the need to develop better as well as groundbreaking ferroptosis targeting therapies which could provide cure in addition to anticipation amidst the populace suffering from cancer across the globe.
Furthermore, an inclining market trend towards utilizing the realm of ferroptosis targeting therapies has been observed due to involvement of various stakeholders from pharmaceutical as well as biotech companies such as MitoImmune Therapeutics, Kojin, PTC Therapeutics, Sumitomo Pharma and Prothegen. With the current market scenario, the future of the ferroptosis targeting therapies market looks promising and is expected to multiple further as evident from the growing clinical trials, mounting research and development and involvement of various stakeholders in the domain.
